Richard DeLuca - Merck President
| MRK Stock | MXN 2,064 36.60 1.80% |
President
Mr. Richard R. DeLuca, Jr. is Executive Vice President and President Merck Animal Health of Merck Co Inc. He is responsible for the Merck Animal Health organization. Prior to September 2011, Mr. DeLuca was Chief Financial Officer, Becton Dickinson Biosciences since 2010 and President, Wyeths Fort Dodge Animal Health division from 2007 to 2010. He served as Chief Operating Officer, Fort Dodge from 2006 to 2007 and Executive Vice President and Chief Financial Officer from 2002 to 2006. since 2011.
| Age | 60 |
| Tenure | 13 years |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Thomas Roos | UnitedHealth Group Incorporated | 50 | |
| Joel Poppen | Micron Technology | 54 | |
| Hans Vestberg | Verizon Communications | 58 | |
| Sumit Sadana | Micron Technology | 54 | |
| Scott DeBoer | Micron Technology | 57 | |
| Matthew Ellis | Verizon Communications | 52 | |
| Michael Bokan | Micron Technology | 62 | |
| David Zinsner | Micron Technology | 49 | |
| Edgard Aguilar | Southern Copper | 67 | |
| Brady Connor | Verizon Communications | N/A | |
| David Wichmann | UnitedHealth Group Incorporated | 56 | |
| John Rex | UnitedHealth Group Incorporated | 61 | |
| William Deckelman | DXC Technology | 65 | |
| Marianne Short | UnitedHealth Group Incorporated | 68 | |
| April Arnzen | Micron Technology | 47 | |
| Manish Bhatia | Micron Technology | 51 | |
| Raul Ruisanchez | Southern Copper | 65 | |
Management Performance
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, General Counsel | ||
| David Williams, Ex Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Lisa LeCointeCephas, VP Officer | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman, CEO and Pres | ||
| Peter Dannenbaum, VP Relations | ||
| Jennifer Mauer, VP Communications | ||
| Robert JD, Pres Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 5.9 T | |||
| Shares Outstanding | 2.54 B | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 469.71 X | |||
| Price To Book | 6.28 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Merck Stock Analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.